2025年12月期 通期 決算説明資料

This document is the financial results presentation for the fiscal year ending December 2025 of GNI Group, Inc. It outlines the company's strategy as a global biopharmaceutical enterprise leveraging markets in Japan, the U.S., and China for sustainable growth. The main business segments include pharmaceuticals, drug discovery, and medical devices, with a focus on developing new treatments for fibrosis and cancer. The lead product, Aisurui, has received new drug approval in China for treating pulmonary fibrosis, while F351 has been designated as a breakthrough therapy for liver fibrosis. The company aims to establish a profitable base in Japan to support its global growth strategy.